Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

ABOS - Acumen Pharmaceuticals, Inc.... | Finranks

Home

ABOS

A

Acumen Pharmaceuticals, Inc. (ABOS)

NMS – Цена в реальном времени. Валюта: USD

2.26

-0.29 (-11.37%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

2.26

0.00 (0.00%)

После закрытия: Mar 27, 2026, 6:31 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the full year ended December 31, 2025 and provided a business update.

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2025 financial results on Thursday, March 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. Acumen expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses.

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026, at 11:00 a.m. ET.

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. ( ABOS ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Alex Braun - VP & Head of Investor Relations Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Business Officer James Doherty - President & Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - BofA Securities, Research Division Thomas Shrader - BTIG, LLC, Research Division Matthew Ryan Tan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and welcome to the Acumen Pharma Third Quarter 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this call may be recorded.

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Alex Braun - VP & Head of Investor Relations Daniel J. O'Connell - CEO & Director Eric Siemers - Chief Medical Officer James Doherty - President & Chief Development Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Jason Eron Zemansky - BofA Securities, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Pete George Stavropoulos - Cantor Fitzgerald & Co., Research Division Trung Chuong Huynh - UBS Investment Bank, Research Division Operator Good day, and welcome to the Acumen Pharmaceuticals Second Quarter 2025 Conference Call and Webcast.

Видео

No Data

There is no data to display